Outlook Therapeutics (OTLK) Proxy filing summary

Executive summary

• Special meeting scheduled for July 16, 2026, to vote on key proposals affecting capital structure and compliance with Nasdaq requirements.

• Proposals include authorizing new share issuances, increasing authorized shares, and a reverse stock split.

• Board recommends voting in favor of all proposals to support ongoing operations and strategic flexibility.

Voting matters and shareholder proposals

• Proposal 1: Approve issuance of up to 16,129,033 shares via private placement warrants, 2,258,064 via placement agent warrants, and 2,142,854 via amended warrants, all tied to recent financing.

• Proposal 2: Amend certificate to increase authorized common stock from 260,000,000 to 600,000,000 shares.

• Proposal 3: Approve a reverse stock split at a ratio between 1-for-10 and 1-for-50, with a proportionate reduction in authorized shares, ratio to be set by the Board.

• Board recommends voting “For” all proposals; failure to approve may require repeated special meetings and could impact funding.

Board of directors and corporate governance

• Board retains discretion to set the reverse split ratio and to implement or abandon the split within one year of approval.

• Board has no current plans for additional share issuances beyond those described, but seeks flexibility for future business needs.